Suven Pharmaceuticals Limited

NSEI:SUVENPHAR Stok Raporu

Piyasa değeri: ₹324.4b

Suven Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Suven Pharmaceuticals'in gelirinin artacağı tahmin edilmektedir.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi17.7%
Gelir büyüme oranı25.5%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Recent updates

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Kazanç ve Gelir Büyüme Tahminleri

NSEI:SUVENPHAR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
3/31/202614,8004,410N/A4,9701
3/31/202513,210N/AN/A3,8101
9/30/20249,6122,4311,8852,838N/A
6/30/20249,3452,405N/AN/AN/A
3/31/202410,5143,0033,0673,585N/A
12/31/202311,6783,709N/AN/AN/A
9/30/202313,0174,3183,1304,318N/A
6/30/202313,4914,243N/AN/AN/A
3/31/202313,4034,1131,7134,572N/A
12/31/202213,3483,790N/AN/AN/A
9/30/202213,7264,3132,5224,787N/A
6/30/202213,9524,563N/AN/AN/A
3/31/202213,2024,5382,5483,300N/A
12/31/202112,1554,453N/AN/AN/A
9/30/202110,9893,9882,5613,465N/A
6/30/202110,3533,759N/AN/AN/A
3/31/202110,0973,6232,7173,825N/A
12/31/20209,3533,534N/AN/AN/A
9/30/20208,3912,9772,5183,843N/A
6/30/20208,7463,166N/AN/AN/A
3/31/20208,3383,1703,0394,069N/A
3/31/20199,0682,623-1531,210N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SUVENPHAR 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: SUVENPHAR 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: SUVENPHAR şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: SUVENPHAR şirketinin gelirinin (yıllık 25.5% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SUVENPHAR şirketinin gelirinin (yıllık 25.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SUVENPHAR 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin